- Conditions
- Healthy
- Interventions
- Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg, CLUCOVANCE® 5 mg/500 mg Tablets, single dose
- Drug
- Lead sponsor
- Actavis Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2002
- U.S. locations
- 1
- States / cities
- Fargo, North Dakota
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1009–1032
of 1,584
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Chin Augmentation, Chin Retrusion
- Interventions
- Restylane Lyft with Lidocaine, Juvederm Voluma XC
- Device
- Lead sponsor
- Galderma R&D
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 175 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Manhattan Beach, California • Westport, Connecticut + 8 more
- Conditions
- Chronic Schizophrenia
- Interventions
- Lurasidone HC1, Quetiapine XR
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 27
- States / cities
- Little Rock, Arkansas • Cerritos, California • Costa Mesa, California + 21 more
- Conditions
- Families Experiencing Homelessness and/or Housing Instability, Housing Stability
- Interventions
- Guaranteed Income, Public Benefits Information Session
- Other
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 2
- States / cities
- San Jose, California
- Conditions
- Endometrial Neoplasms
- Interventions
- pembrolizumab, carboplatin, paclitaxel, docetaxel, cisplatin
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 35
- States / cities
- Phoenix, Arizona • La Jolla, California • Riverside, California + 28 more
- Conditions
- Huntington Disease
- Interventions
- SKY-0515, SKY-0515 Placebo
- Drug
- Lead sponsor
- Skyhawk Therapeutics, Inc.
- Industry
- Eligibility
- 25 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 4
- States / cities
- Englewood, Colorado • Boston, Massachusetts • Charlestown, Massachusetts + 1 more
- Conditions
- Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
- Interventions
- Samalizumab (BAML-16-001-S1), BI 836858 (BAML-16-001-S2), Laboratory Biomarker Analysis, Daunorubicin (BAML-16-001-S1), Cytarabine (BAML-16-001-S1), Azacitidine (BAML-16-001-S2), AG-221 (BAML-16-001-S3), Azacitidine (BAML-16-001-S3), Entospletinib (BAML-16-001-S4), Azacitidine (BAML-16-001-S4), Entospletinib (BAML-16-001-S5), Decitabine (BAML-16-001-S5), Entospletinib (BAML-16-001-S6), Daunorubicin (BAML-16-001-S6), Cytarabine (BAML-16-001-S6), Pevonedistat (BAML-16-001-S9), Azacitidine (BAML-16-001-S9), AG-120 (BAML-16-001-S16), Azacitidine (BAML-16-001-S16), Gilteritinib (BAML-16-001-S8 Group 1), Decitabine (BAML-16-001-S8 Group 1), AZD5153 (BAML-16-001-S10), Venetoclax (BAML-16-001-S10), TP-0903 (BAML-16-001-S14), Decitabine (BAML-16-001-S14), Decitabine (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S8 Group 2), AZD5991 (BAML-16-001-S18), Azacitidine (BAML-16-001-S18), SNDX-5613 (BAML-16-001-S17), Azacitidine (BAML-16-001-S17), Venetoclax (BAML-16-001-S17), Gilteritinib (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S12 Arm A), Azacitidine (BAML-16-001-S12 Arm A), Venetoclax (BAML-16-001-S12 Arm B), Azacitidine (BAML-16-001-S12 Arm B), ZE46-0134 (BAML-16-001-S21 Group 1), ficlatuzumab (BAML-16-001-S24), Azacitidine (BAML-16-001-S24), Venetoclax (BAML-16-001-S24), ZE46-0134 (BAML-16-001-S21 Group 2), Bleximenib (BAML-16-001-S25/HO181), Cytarabine (BAML-16-001-S25/HO181), Daunorubicin or Idarubicin (BAML-16-001-S25/HO181), Placebo (BAML-16-001-S25/HO181), Revumenib (BAML-16-001-S26/HO177), Placebo (BAML-16-001-S26/HO177)
- Biological · Other · Drug
- Lead sponsor
- Beat AML, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2032
- U.S. locations
- 31
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 26 more
- Conditions
- Tooth Sensitivity
- Interventions
- Prof applied oxalate, Self applied oxalate, Prof applied placebo
- Device
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Sepsis, Septicemia, Respiratory Failure, Hemodynamic Instability, COVID-19, Cardiac Arrest, Clinical Deterioration
- Interventions
- eCARTv5 clinical deterioration monitoring, Standard of care control
- Device · Other
- Lead sponsor
- AgileMD, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 3
- States / cities
- New Haven, Connecticut • Clearwater, Florida • Madison, Wisconsin
- Conditions
- Non-Small Cell Lung Cancer, Advanced Solid Tumors, Gastroesophageal Adenocarcinoma, Colorectal Cancer
- Interventions
- ABBV-400, Trifluridine/Tipiracil, Bevacizumab
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 520 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 18
- States / cities
- Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 13 more
- Conditions
- Musculoskeletal Manipulations
- Interventions
- Spinal Manual Therapy, Spinal Range of Motion
- Procedure
- Lead sponsor
- Shenandoah University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Winchester, Virginia
- Conditions
- Mental Disorder, Child, Mental Health, Family Health
- Interventions
- Parent Peer Navigation
- Behavioral
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 1 Year to 99 Years
- Enrollment
- 240 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 4
- States / cities
- Aurora, Colorado • Salem, Oregon • Pittsburgh, Pennsylvania + 1 more
- Conditions
- Cognition - Other, Depression, Anxiety
- Interventions
- Black rice extract, Placebo
- Dietary Supplement · Other
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Davis, California
- Conditions
- Chemotherapy-related Cognitive Impairment
- Interventions
- Low-Intensity Walking Intervention, Control Group Intervention
- Behavioral
- Lead sponsor
- Ellis Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Schenectady, New York
- Conditions
- Posttraumatic Stress Disorder
- Interventions
- Comparator Dose (40mg) MDMA HCl, Active Dose 2 (100 mg) MDMA HCl, Active Dose 1 (125 mg) MDMA HCl, Psychotherapy
- Drug · Behavioral
- Lead sponsor
- Resilient Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Boulder, Colorado
- Conditions
- Actinic Keratoses
- Interventions
- Test Product (A): Fluorouracil Cream, 5% topical cream, Reference Product (B): Fluorouracil 5% Topical Cream of Mylan Pharmaceuticals Inc., Morgantown, WV 26505 U.S.A., Placebo Product (C): Test vehicle cream for fluorouracil 5% of Encube Ethicals Pvt. Ltd., India
- Drug
- Lead sponsor
- Encube Ethicals Pvt. Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 458 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 7
- States / cities
- Bakersfield, California • Cerritos, California • Lauderdale Lakes, Florida + 3 more
- Conditions
- Urinary Retention
- Interventions
- 30 cm Intermittent Catheter, 40 cm Intermittent Catheter
- Device
- Lead sponsor
- Hollister Incorporated
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • Wheeling, Illinois • Kansas City, Missouri + 1 more
- Conditions
- Healthy
- Interventions
- meropenem-vaborbactam, Placebo, Moxifloxacin
- Drug
- Lead sponsor
- Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Type 2 Diabetes, Insulin Resistance, Metabolic Syndrome
- Interventions
- metformin, pioglitazone, Placebo
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 20 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Rheumatoid Arthritis
- Interventions
- KB003, Placebo Comparator
- Biological · Other
- Lead sponsor
- Humanigen, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 11
- States / cities
- Stanford, California • Westlake Village, California • Miami, Florida + 7 more
- Conditions
- Healthy
- Interventions
- Nabumetone 750 mg tablets, single dose
- Drug
- Lead sponsor
- Actavis Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007
- U.S. locations
- 1
- States / cities
- Morrisville, North Carolina
- Conditions
- Upper Extremity Paresis, Stroke, Chronic
- Interventions
- NeuraStasis Stimulator System (Non-Invasive Trigeminal and Vagus Nerve Stimulation), Upper Limb Rehabilitation, Sham Stimulation
- Device · Other
- Lead sponsor
- NeuraStasis, Inc
- Industry
- Eligibility
- 30 Years to 85 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF)
- Interventions
- ANG003 Dose A, ANG003 Dose B, Creon
- Drug
- Lead sponsor
- Anagram Therapeutics, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 113 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 28
- States / cities
- Long Beach, California • Los Angeles, California • Denver, Colorado + 24 more
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Rezpegaldesleukin, Placebo
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 8 Years to 45 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 14
- States / cities
- San Francisco, California • Aurora, Colorado • New Haven, Connecticut + 11 more